NEW YORK (TheStreet) -- "This is one of these markets where you're finally seeing money come in," said Jim Cramer on CNBC's "Stop Trading!" on Monday. "It's the beginning of the movement for the public into the stock market."

Cramer said that up till now "the retail investor hasn't touched this market at all."

He pointed to

Merck

(MRK) - Get Report

and

Boeing

(BA) - Get Report

, which he said are both "flying" in spite of "so much negative news" over the past few days. He said he's "very pro-Boeing" and has been recommending it on his "Mad Money" show, noting that with its dividend "you get paid to wait."

Cramer said he also likes

Intel

(INTC) - Get Report

. "You can't have a

Dell

(DELL) - Get Report

upgrade without thinking good things about Intel," he said. "You can't have

Microsoft

(MSFT) - Get Report

do well without Intel doing well."

He said Intel "was waiting to get through the settlement with

AMD

(AMD) - Get Report

, and that the "regular dividend-increaser" is "putting up a sign that says, 'Listen, you don't understand how good things are.'"

Finally, he gave a nod to

Bristol-Myers Squibb

(BMY) - Get Report

, which he owns for his

Action Alerts PLUS

charitable trust and whose

Mead Johnson

(MJN)

split-off should bring in some cash, he said.

He named

Exelsis

(EXEL) - Get Report

,

Allos Therapeutics

(ALTH)

and

Immunogen

(IMGN) - Get Report

as potential targets for Bristol, all of which "would increase its cancer franchise."

He said CEO James Cornelius is "fabulous" and operates under the "string of pearls philosophy" of small acquisitions. "Cornelius is money in the bank," Cramer said.

-- Written by Rebecca Corvino in New York.

(Editor's note: At the time of publication, Cramer owned Bristol-Myers for his Action Alerts PLUS charitable trust.)